Sage Therapeutics Inc

0.055 (0.11%)


Draw Mode:

Volume 127,083
Bid Price 49.54
Ask Price 49.58
News -
Day High 50.105


52 Week Range


Day Low 48.67
Company Name Stock Ticker Symbol Market Type
Sage Therapeutics Inc SAGE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.055 0.11% 49.555 15:07:13
Open Price Low Price High Price Close Price Prev Close
49.36 48.67 50.105 49.50
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,742 127,083 $ 49.53 $ 6,294,836 - 30.665 - 54.86
Last Trade Time Type Quantity Stock Price Currency
15:07:19 3 $ 49.54 USD

Sage Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.96B 59.76M 51.28M $ 3.29M $ -1.47M -2.46 -2,017.19
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 11.22k 0.30%

more financials information »

Sage Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No SAGE Message Board. Create One! See More Posts on SAGE Message Board See More Message Board Posts

Historical SAGE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week51.3751.149948.8949.57412,443-1.82-3.53%
1 Month47.3454.8646.037551.25465,5922.224.68%
3 Months44.8254.8638.66546.27523,4814.7410.56%
6 Months40.9254.8636.9144.19507,3048.6421.1%
1 Year31.6354.8630.66540.09556,16317.9356.67%
3 Years35.6198.38527.3649.71615,07213.9539.16%
5 Years154.33193.5625.0170.87637,180-104.78-67.89%

Sage Therapeutics Description

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development.